The 51st Annual American Congress of Hematology was held in New Orleans, USA, from December 5 to 8, 2012. During the meeting Prof. Verstovsek from Anderson Cancer Center gave a summary on the progress of myeloproliferative disorders, and the authors concluded that an activated tyrosine kinase mutation has been identified in patients with myeloproliferative neoplasms, true erythroblastosis, primary thrombocythemia, and primary myelofibrosis – -JAK2V617F, and drugs targeting JAK2V617F have recently been tested in clinical trials abroad, including INCB018424, TG101348, XL019, and CEP701. Phase I clinical trials found that patients applying INCB018424, 25 mg twice daily, could effectively control Further studies found that INCB018424 normalized the over-activated STAT signaling pathway and significantly inhibited the secretion of interleukin-1, tumor necrosis factor-alpha, interleukin-6, vascular endothelial growth factor, and fibroblast growth factor. Phase III clinical trials are currently underway, and if successful, targeted therapies such as INCB018424, like imatinib for chronic granulocytic leukemia, will be available in the near future for patients with myeloproliferative neoplasms, true erythroblastosis, primary thrombocytosis, and primary myelofibrosis. myelofibrosis.